The richest companies on Earth pay Elon rent

Hey there, bargain hunter. The vaccine company everyone wrote off as a COVID one-trick pony just handed Wall Street a reality check.

Scoreboard

Moderna reported Q3 2026 earnings of $0.38 per share, crushing the consensus estimate of negative $1.10, on revenue of $1.31 billion. That revenue figure was up 29% from the year-ago period. The company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. Shares climbed about 5% on the news.

What Actually Happened

The beat was not a one-line story. Two things drove it simultaneously: geography and cost discipline. International demand, including deliveries under long-term strategic government partnerships with the United Kingdom, Canada, and Australia, boosted results, while work to lower costs flipped the quarter into profit. The street had modeled a loss. What arrived was $162 million in net income.

But the number that matters most to anyone thinking about MRNA’s next three years is not on the income statement.

The Cancer Pipeline Is No Longer Hypothetical

In late October, Moderna and Merck put the data investors have been waiting years for on the table, including in presentations at ESMO 2026. Positive Phase 3 results from the INTerpath-001 study in resected high-risk melanoma showed that intismeran autogene (mRNA-4157) in combination with Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone, based on recurrence-free survival, the trial’s primary endpoint. The benefit sharpened after six months, with the combination reducing recurrence or death risk by 58% in a pre-specified sensitivity analysis (a piecewise look at the curves after the immunization regimen).

That is not a signal. That is a Phase 3 result in a fully enrolled trial. Moderna and Merck are now working toward regulatory submissions and preparing for a potential commercial launch.

Is It Cheap?

Oncology remains pre-revenue, and the larger fixed cost base still leans on COVID-weighted sales. So MRNA is not cheap by conventional metrics. What it is, is priced on optionality. The market has spent two years treating Moderna as a vaccine roll-off story. A profitable quarter plus a Phase 3 oncology win forces a different question: what does the mRNA platform earn when it has two commercial franchises instead of one?

The oncology repricing story is not unique to Moderna. AstraZeneca converted modest top-line growth into 20% profit growth by leaning on an oncology franchise that now makes up nearly half of quarterly revenue.

The pipeline beyond melanoma widens that potential. The INTerpath program now consists of nine Phase 2 and Phase 3 trials across multiple tumor types and stages, including three ongoing Phase 3 trials in non-small cell lung cancer.

Bull / Base / Bear

• Bull: Regulatory approval for intismeran arrives in 2027. Geographic vaccine expansion continues to compound. MRNA rerate toward a multi-product biotech multiple.
• Base: Vaccine revenue holds the new guidance band. Oncology approval takes until late 2027. Stock grinds higher on fundamentals rather than catalyst.
• Bear: Norovirus still lacks a clear path after missing early criteria, and a COVID demand reset in 2027 exposes the fixed cost base before oncology revenue can offset it.

Bottom Line

If the INTerpath-001 melanoma data translates into a 2027 approval, Moderna stops being a vaccine-rolloff trade and becomes a two-platform growth company. The Q3 profit proves the base business can fund the transition. The question is timing. Buy in tranches if you believe the oncology catalyst arrives before the COVID revenue cycle turns down again.